Spero Therapeutics Net Income 2016-2021 | SPRO

Spero Therapeutics net income from 2016 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Spero Therapeutics Annual Net Income
(Millions of US $)
2020 $-78
2019 $-61
2018 $-42
2017 $-46
2016 $-30
2015 $-13
Spero Therapeutics Quarterly Net Income
(Millions of US $)
2021-09-30 $-23
2021-06-30 $-19
2021-03-31 $-19
2020-12-31 $-19
2020-09-30 $-19
2020-06-30 $-18
2020-03-31 $-23
2019-12-31 $-25
2019-09-30 $-18
2019-06-30 $-13
2019-03-31 $-5
2018-12-31 $-11
2018-09-30 $-10
2018-06-30 $-10
2018-03-31 $-11
2017-12-31 $-15
2017-09-30 $-12
2017-06-30 $-12
2017-03-31 $-7
2016-12-31
2016-09-30 $-7
2015-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.427B $0.009B
Spero Therapeutics Inc. is a multi-asset, clinical-stage biopharmaceutical company. It focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections. Spero Therapeutics Inc. is based in CAMBRIDGE, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $144.122B 9.11
Bio-Rad Laboratories (BIO.B) United States $18.677B 37.90
QIAGEN (QGEN) Netherlands $11.053B 18.72
Biohaven Pharmaceutical Holding (BHVN) United States $8.002B 0.00
Emergent Biosolutions (EBS) United States $2.809B 10.10
Arcus Biosciences (RCUS) United States $2.516B 0.00
Myovant Sciences (MYOV) United Kingdom $1.432B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.186B 0.00
Zymeworks (ZYME) Canada $0.697B 0.00
Ambrx Biopharma (AMAM) United States $0.230B 0.00
SQZ Biotechnologies (SQZ) United States $0.229B 0.00
Enzo Biochem (ENZ) United States $0.160B 20.69